Research Article

HuR Promotes the Progression of Gastric Cancer through Mediating CDC5L Expression

Jing Cui,1 Nanjing Cao,2,3 Guochao Wang,4 Fuhua Wang,3 Bin Yang,5 Jian Wang,5 Yongqiang Lv,6 Yunqing Chen6,5 and Feng Li3

1Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan 030001, China
2Department of Clinical Laboratory, Xi’an Da Xing Hospital, No. 353, North Labor Road, Xi’an 710016, China
3Department of Cell Biology, Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030012, China
4Radiation Oncology Center, Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030012, China
5Surgical VIP, Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030012, China
6Shanxi Cancer Hospital, Affiliated Cancer Hospital of Shanxi Medical University, Taiyuan 030012, China

Correspondence should be addressed to Yunqing Chen; chenmao1965@sina.com and Feng Li; lifenglover@sina.com

Received 17 December 2021; Revised 9 February 2022; Accepted 11 February 2022; Published 12 March 2022

1. Introduction

Gastric cancer (GC) is one of the most common gastrointestinal tumors. In China, the diagnosis and treatment rates of early GC are less than 10%. The 5-year survival rate is about 30% after radical resection of advanced [1]. Clinical statistics show that the incidence and death rate of GC is high, but the early diagnosis rate and 5-year survival rate are low. The pathogenesis of GC has yet to clear, but the diagnosis of 80%~90% of progression has spread to the lymph nodes and even distant metastasis over time. Lymph node metastasis of GC, nearly 20%, is the main route of GC metastasis. Studies have shown that lymphatic metastasis of GC is an important factor affecting the prognosis of early GC [2]. Therefore, it is of great clinical significance to explore the related factors of GC metastasis, early prediction of the risk of lymph node metastasis to improve the survival rate of patients.

Human antigen receptor (HuR) belongs to the RNA binding protein family, embryonic lethal abnormal vision (ELAV). It is known as the class embryonic death abnormal visual, widely expressed in mammalian cells [3]. HuR was first detected in the serum from lung cancer patients in 1990. In 1996, Ma et al. [4] applied the polymerase chain reaction (PCR) technology identifying and cloning HuR. HuR includes four members: HuB, HuC, HuD, and HuR. The first three members are mainly expressed in neural tissues and reproductive organs and related to neural development. HuR can be connected with multiple regulatory factors such as Von Hippel Lindau tumor suppressor
2. Materials and Methods

2.1. Clinical Specimens and Cell Culture. GC tissue and paired adjacent normal tissue samples from 80 patients were collected from Shanxi Cancer Hospital/Institute. GC tissue microarrays were from Shanghai Qiagen Biotech (China). The ethical board approved the experiment by the Shanxi Cancer Hospital/Institute. GC tissues were obtained with the patient’s informed content and were confirmed by clinical. GC cell lines BGC-823, MKN-45, MGC-803, SGC-7901, and AGS were obtained from the ATCC. GC cells were grown in a 5% CO₂ culture incubator with 10% FBS DMEM (Hyclone, Utah) at 37°C. Mycoplasma detected cell lines according to the verification recommendations of the ATCC.

2.2. RNA Isolation and qRT-PCR Analysis. Total RNA was extracted from the cultured cells using TRIzol reagent (Invitrogen, CA, USA). RNA isolation and quantitative real-time PCR (qPCR) analysis were conducted with the Vii7 Q-PCR system (ABI, USA) in the Thermal Cycler Dice Real-time PCR (qPCR) analysis were conducted with the Vii7 Q-PCR system (ABI, USA) in the Thermal Cycler Dice Real-time PCR (qPCR) system (Takara). The qPCR primers are listed in Table 1.

2.3. Oligonucleotide. Cells were transfected (100 nM) with HuR (si-HuR) and control siRNA (si-control) using Lipofectamine TM 2000 (Invitrogen, USA). The results were measured relative to light units per luciferase activity by qRT-PCR.

2.4. Cell Proliferation and Migration. In cell proliferation, si-HuR and si-control transfected GC cells were seeded in 96-well plates at 2000 cells per well. The assay was evaluated by 10% CCK-8 (DOJINDO) diluted on a microtiter plate reader (Spectra Rainbow, Tecan) after 1, 2, 3, and 4 days posttransfection. Proliferation rates were determined under the manufacturer’s recommended protocol.

In wound-healing assays, GC cells were transfected with si-HuR and si-control on 6-well plates. Linear scratch wounds were created after 1 day of transfection in a serum-free medium. The degree of convergence was obtained at every 24 h. Each group had three duplicate holes.

2.5. Colony Formation Assays. Transfected cells were growing in 24-well plates at 1 × 10⁵ cells per well. Cells treated with trypsin were maintained in an incubator for 7-10 days. Then, the cells were washed with PBS, fixed with formalin, and stained with methyl violet. The number of colonies was counted using a microscope (Olympus IX-7, Japan) [35].

2.6. Cell Cycle Assay. Si-HuR and si-control transfected GC cells were seeded at 3 × 10⁶ cells per well in 6-well plates. The cells were maintained in complete medium for 2 days. By using precooling, 1 × PBS contained EDTA washing cells twice, suspending cells, blending, and washing cells. The cell cycle of GC cells was examined after treatment with si-HuR or si-control and staining with PI.

2.7. Luciferase Assay. After 48 h of cell transfection, the old culture medium was sucked off and washed twice with PBS. PLB (Passive Lysis Buffer) of 100 μL was added to each cell hole. Then, it was shaken gently for 10-15 minutes and collected the cell lysate. Then, we added 100 μL LAR II working fluid to each sample, mixed it immediately and read the value 2 s, added 100 μL Stop & Glo® Reagent, mixed it quickly, and put it into the luminescent detector to read the value 2 s.

2.8. Tumorigenicity Assay In Vivo. Animal experiment was conducted according to the guide for the Care and Use of Laboratory Animals (NIH publications nos. 80–23, revised 1996) and the institutional ethical guidelines for animal experiments. si-control and si-HuR transduced GC cells (1 × 10⁷) with 100 μL of PBS were placed into one side of the posterior flank of the nude mouse at 5-6 weeks of age. Tumor growth was examined and tumor volume (V) was monitored with the width (W) and length (L) (V = (L × W²) × 0.5).

2.9. Immunoblotting Analysis. GC cells were cultured in 8-well chamber slides (Thermo Scientific), then fixed, washed, incubated (0.01% NaAzide, 3% BSA, TBS pH 7.8, 1% Triton X-100, 1% normal goat serum), and stained. At last, they were incubated with an IgG-antibody (Life Technologies) and captured images by Zeiss microscope.

2.10. Immunohistochemistry and H&E Staining. In H&E staining, GC tissues were embedded, sectioned, dewaxed, and hydrated. Then, tissues were incubated with antibodies,
stained with hematoxylin and eosin (H&E), and observed with a microscope finally. For immunohistochemistry, 0.3% H₂O₂ was incubated for 15 minutes and antigen was extracted from 0.01 M sodium citrate-hydrochloric acid buffer. HuR (Proteintech) and GAPDH (Cell Signaling Technology) antibodies were used for immunohistochemical analysis. Cells were viewed and photographed with a Zeiss UV LSM confocal microscope.

3. Results

3.1. Abnormal Expression of HuR in Human Cell Lines and GC Tissues. To determine the expression of HuR (ELAVL1, ELAV like RNA binding protein 1) in GC, 80 pairs of clinic GC tissues and matched adjacent normal tissues were analyzed with quantitative PCR (qPCR). Results show that the expression of mRNA in 66 cases (82.5%) was rising in tumor tissues compared with their normal tissues, while only 14 cases (17.5%) showed a reduced level in GC (Figure 1(a)). Therefore, the overall expression of HuR in GC tissues was upregulated significantly (Figure 1(b), p < 0.001, GC vs. normal). To further study the relationship between the expression of HuR and the development of GC, we analyzed the relationship between metastatic and nonmetastatic of GC and the level of HuR statistically (nonparametric test). We found that a high HuR level was associated with the pM stage (Figure 1(c), p < 0.001, metastasis vs. nonmetastasis) in GC patients. However, there was no significant difference between HuR and other clinicopathological features such as Borrmann typing, age, position, gender, and venous invasion. Besides, overall survival and disease-free survival were significantly worse in GC patients with high HuR expression (Figure 1(d)).

For further determination, we examined HuR protein levels in 6 pairs of GC samples. In parallel with mRNA expression changes, the HuR protein levels were escalated significantly in GC tissues (>1.7-fold) compared with normal tissues (Figure 1(e)). Moreover, we used five GC cell lines (MKN-45, SGC-7901, AGS, BGC-823, and MGC-803) and normal cells to analyze the expression of the protein. It was shown that HuR was also elevated in GC cell lines in comparison with normal cells (Figure 1(f)). These results indicated that HuR was a potential oncogene in GC tumorigenesis.

3.2. HuR Promotes GC Cell Proliferation and Migration. Upregulated HuR expression in GC tissues was reminded us to explore the function of HuR in GC tumorigenesis. We selected SGC-7901 and MGC-803 cell lines to disclose the role of HuR in the pathogenesis of GC, in which the

| Name   | Forward | Reverse |
|--------|---------|---------|
| CDC5L  | Forward | GAGAGCTCTCACGATGAGCTTA |
|        | Reverse | TCTTCTTTCCCACTCTTTCGACG |
| BCAS2  | Forward | ACCGACCTAAGAAGACTACCT |
|        | Reverse | ATCTTGGCATGACATTAAGTC |
| PTBP1  | Forward | TCAATTGTGGTGTTATTTCCT |
|        | Reverse | GCAGGTCCTACAGTCAAGATTC |
| TRA2B  | Forward | GCAGGTCCTACAGTCAAGATTC |
|        | Reverse | TCTTCTTTCCCACTCTTTCGACG |
| SRSF3  | Forward | AGAATACCTTGAACCCAGGGG |
|        | Reverse | TTCTTCTTTCCCACTCTTTCGACG |
| SF3B1  | Forward | ATCTTGGCATGACATTAAGTC |
|        | Reverse | GCAGGTCCTACAGTCAAGATTC |
| SF3A1  | Forward | GCAGGTCCTACAGTCAAGATTC |
|        | Reverse | TCTTCTTTCCCACTCTTTCGACG |
| HNRNPC | Forward | ACAGATCCATGGTCCATGAACCTC |
|        | Reverse | TTCTTCTTTCCCACTCTTTCGACG |
| PLRG1  | Forward | AGAATACCTTGAACCCAGGGG |
|        | Reverse | TCTTCTTTCCCACTCTTTCGACG |
| HuR    | Forward | AAGCCTGTTCACGACGATTT |
|        | Reverse | TTCTTCTTTCCCACTCTTTCGACG |
| GAPDH  | Forward | TCAGCCACCACTTTCATGCACT |
|        | Reverse | GCTTGTGTGTCAGGTCATTACT |
| miR-133b mimics | Forward | CGUGUUGAGCGGAGCCAAAUU |
|        | Reverse | UUCUCCGAACGUGUACGUGT |
| miR-133b nc | Forward | AAGCCTGTTCACGACGATTT |
HuR expression was higher than other cells (Figure 1(f)). After transfecting si-HuR into SGC-7901 and MGC-803 cells, we confirmed the efficiency of low HuR expression. Compare with the empty vector si-control, the level of HuR protein was reduced in SGC-7901 and MGC-803 cells treated with si-HuR (Figure 2(a)). Then, we used propidium iodide staining assay to assess the effect of si-HuR on the cell cycle. As expected, the percentage of S-phase cells reduced markedly after being treated with si-HuR in SGC-7901 and MGC-803 cells (Figure 2(b)). Accordingly, the low

Figure 1: Expression of HuR in GC tissues and cell lines. (a) Relative abundance of HuR was detected in 80 pairs of GC cancers and adjacent normal cancers by RT-qPCR. (b) Scatter plots show the relative HuR mRNA level between cancer tissues and normal tissues. (c) The statistical analysis of the association between the HuR level and pM stage (metastasis and no metastasis). (d) Statistical analysis of survival probability of HuR high- (n = 26) and low-expressing (n = 6) GC patients using Kaplan–Meier analysis. Statistical analysis is described in the Materials and Methods. (e) Immunoblotting analysis of HuR proteins in 6 pairs of GC samples. GAPDH was used as a loading control. The HuR expression level was normalized to loading control. (f) Levels of HuR protein in GC cell lines (MKN-45, SGC-7901, AGS, BGC-823, and MGC-803) relative to one normal control sample. For all qPCR results, the data are presented as the mean ± SEM, and the error bars represent the standard deviation obtained from three independent experiments. *p < 0.05; **p < 0.01.
Figure 2: Functional analysis of HuR in GC cells. (a) HuR levels were detected in SGC-7901 and MGC-803 cells after treatment with si-HuR or si-control by immunoblotting. (b) Flow cytometry was conducted to examine the cell cycle of SGC-7901 and MGC-803 cells after treatment with si-HuR or si-control and staining with PI. (c) Cell proliferation assay of SGC-7901 and MGC-803 cells after treatment with si-HuR or si-control using CCK-8. (d) Wound healing assays of SGC-7901 and MGC-803 cells after treatment with si-HuR or si-control. The relative ratio of wound closure per field is shown in the right. (e) Clone formation assay of SGC-7901 and MGC-803 cells after treatment with si-HuR or si-control. For all qPCR results, the data are presented as the mean ± SEM, and the error bars represent the standard deviation obtained from three independent experiments. *p < 0.05; **p < 0.01.
expression of HuR pointed to more sluggish proliferation rate than controls after CCK-8 assay (Figure 2(c)). Moreover, clonogenic tests were indicated a noticeable decline in cell proliferation after si-HuR transfection into both SGC-7901 and MGC-803 cells (Figure 2(d)).

Based on the communication between HuR expression and GC tumorigenesis, we suggested that the protein might regulate some cell functions of GC cells. To verify this hypothesis, we performed cell migration assays in SGC-7901 and MGC-803 cells with si-HuR or si-control treated. To compare with the si-control, the wound healing degree was decreased in si-HuR GC cells (Figure 2(e)). The above results vouched that HuR may act as an oncogene by promoting cell migration and proliferation, as well as promoting the cell cycle in GC cells.

3.3. HuR Promotes Tumor Cell Growth and Metastasis In Vivo. We further validated these findings in mouse models by subcutaneous injection of (s.c.) si-HuR or si-control lentivirus MGC-803 cells on the posterior flank of nude mice. The animals were sacrificed after six weeks. Low HuR expression was suppressed tumor growth significantly compared with the control group (Figure 3(a)). The mean final tumor volume was 217 mm$^3$ and 355 mm$^3$, respectively (Figure 3(b)). Final tumor weights were 2207 mg and 3446 mg, respectively. Similarly, immunohistochemistry showed that HuR staining was increased clearly in GC tissues (Figure 3(d)). Hematoxylin and eosin (H&E) staining showed that HuR expression increased further compared with adjacent normal tissues (Figure 3(d)). Thus, HuR may mediate tumorigenesis by promoting the degree of migration and proliferative in GC cells. The findings above reminded us that the HuR was played a visible role in tumor oncogenes in GC cells.

3.4. HuR Regulates the Expression of miR-133b in GC Cells. Recent work by Qin et al. has revealed that the appearance of HuR could mediate the miR-133b level in esophageal squamous cell carcinoma [7]. Furthermore, the changes of contents of miR-133b were revealed in other human cancers, including glioma [8], colorectal [9], and lung cancers [10]. After that, we used MGC-803 cells with a high endogenous HuR level through si-HuR transfection to detect how HuR regulated the expression of miR-133b in GC cells. miRNA array was performed to confirm the changes in HuR gene level leading to changes in miRNA (Figure 4(a)). In MGC-803 cells, si-HuR was considerably increased in miR-133b mRNA levels compared with si-control (Figure 4(a)). We determined significant enrichment of the HuR group and control group for normalizing expression. Biological replicates were analyzed by statistical methods showed a strong correlation. (Figure 4(b)). Luciferase reporter assay verified that the HuR was reduced in luciferase expression of miR-133b compared to NC (Figures 4(c) and 4(d)). Our data implied that HuR and miR-133b were a very close relationship in GC cells.

3.5. miR-133b Functions as a Tumor Suppressor in GC. Based on the above findings, we selected 60 case tissues to study the mysterious effect of miR-133b. QPCR showed that the levels of miR-133b in normal tissues were increased compared with the cancer tissue cells (Figure 5(a)). To confirm the weakening effects of miR-133b on GC development, the known expression miRNAs were used as control (Figure 5(b)). Compared with high miR-133b expression GC patients, the low miR-133b expression had markedly worse overall (Figure 5(c)). We also found that a high miR-133b level impacted GC progression (Figure 5(d)), $p < 0.001$, nonmetastasis vs. metastasis) in GC patients. The CCK-8 proliferation assay in MGC-803 and SGC-7901 cells showed that cell growth was suppressed more severely after transfection with miR-133b mimics (Figure 5(e)). Moreover, clonogenic assays indicated an uncommon reduction in cell proliferation after miR-133b mimics transfection into SGC-7901, MGC-803, and BGC-823 cells (Figure 5(f)). These findings tell us that miR-133b had a tumor suppressor role in GC cells.

3.6. HuR and miR-133b Affect the Expression of CDC5L in GC Cells. GO analysis (string analysis) revealed that most of the interacting genes were splicing factors and transcriptional regulatory genes, especially CDC5L (cell division cycle 5-like protein), acted as a transcription activator (Figure 6(a)). We compared the expression of CDC5L between GC cell lines and normal cells (Figure 6(b)) and selected MGC-803 and BGC-823 for candidate cells. As shown in Figure 6(c), CDC5L displayed the obvious lessen upon HuR knockdown. Given its oncogenic roles in some cancers, colorectal [14] and hepatocellular [15] cancers, we selected CDC5L for western blot analysis. Western blot analysis confirmed that HuR and miR-133b were upstream of CDC5L in MGC-803 and BGC-823 cells (Figure 6(d)).

The introduction of si-HuR into MGC-803 cells would weaken the expression of CDC5L and BCL2. However, we also detected the opposite changes in Cyclin B, P53, and caspase-3 protein expression after knockdown HuR expression in MGC-803 cells. Consistent with the reduced HuR levels in MGC-803 cells, the CDC5L level was markedly lower in BGC-823 cells compared with that in si-control (Figure 6(d)). Therefore, the novel miR-133b-HuR-CDC5L axis was present in GC cells (Figure 6(e)).

4. Discussion

GC, the third most lethal tumor, is a common gastrointestinal cancer worldwide, especially in some countries in East Asia and Eastern Europe [16]. GC is often diagnosed at the advanced stage, accompanied by malignant cell growth and metastasis. In recent years, considerable progress has been made in the clinical treatment of GC, but the survival rate of patients with GC is still not satisfactory [17–19]. Although scientists have identified several related oncogenes or tumor suppressor genes that are identified as crucial regulators of GC, few have been recognized or treated for early clinical screening [20]. Therefore, it is of great significance for clinical treatment to research new markers of GC and explore the related mechanism. In this study, we confirmed an RNA-binding protein, HuR, which is upregulated in GC
patients. The reduced expression of HuR could inhibit the occurrence and development of GC, providing a new strategy for the treatment of GC.

Human antigen receptor (HuR) belongs to the RNA binding protein family and embryonic lethal abnormal vision (ELAV). Moreover known as the class embryonic death abnormal visual, widely expressed in mammalian cells [3]. It has been found to affect mRNA translation [21], cell responses [22], and inflammatory tumor formation [6]. In recent years, more studies have found that HuR is associated with the occurrence and prognosis of different carcinoma, glioma [8], breast cancer [9], lung cancer [10], and colorectal cancer [11]. The HuR regulated COX-2 has been shown to promote the progression of nonsmall cell lung carcinoma [23]. HuR also regulates E-cadherin expression and barrier function [24]. Additionally, HuR regulates AKT phosphorylation level through the PI3K/AKT/NF-κB signaling pathway [25]. Although numerous studies have strongly demonstrated that HuR promotes the progression of many cancers [26], the targets and functional mechanisms are only beginning. We established the axis between HuR miR-133b in GC in the study.

**Figure 3:** HuR promotes GC cell growth in vivo. (a) Xenograft model in nude mice. si-HuR or si-control transfected MGC-803 cells were injected s.c. into the posterior flank of nude mice. The graph is representative of tumors in mice at five weeks after inoculation. The right photo is representative of excised tumors from killed mice. (b) Tumor volume was calculated and all data are shown as the mean ± SD. (c) Tumor weight was calculated and all data are shown as the mean ± SD. (d) Pathology analysis of tumor sections from GC tissues and adjacent normal tissues. Immunohistochemistry, H&E staining, and labeling with HuR were performed. Bars: 20 μm. *p < 0.05; **p < 0.01.
**Figure 4:** HuR regulates the expression of miR-133b in GC cells. (a) Relative expression of miR-133b and total miRNA in HuR knockdown cells as described. (b) Enrichment of HuR group and control group for normalized expression. (c) Luciferase reporter assay was conducted with HuR and mut-HuR. (d) Luciferase reporter assay detected the changes in fluorescence activity of mir-133b group and blank group in transfected 3’ UTR HuR gene or mut 3’ UTR HuR gene. Statistical analysis using Kaplan–Meier analysis. Statistical analysis is described in Materials and Methods. *p < 0.05; **p < 0.01.
Figure 5: Functional analysis of miR-133b in GC cells. (a) miR-133b levels were detected in 60 pairs of GC tissues and adjacent normal regions by RT-qPCR. (b) Heat maps show the expression of miR-133b and known miRNAs in normal cells and GC cell lines. (c) Statistical analysis of survival probability of miR-133b high- (n = 10) and low-expressing (n = 40) GC patients using Kaplan–Meier analysis. Statistical analysis is described in the Materials and Methods. (d) The statistical analysis of the association between miR-133b level and pM stage (metastasis and no metastasis). (e) Cell proliferation assay of SGC-7901 and MGC-803 cells after treatment with miR-133b mimics or miR-133b nc using CCK-8. (f) Clone formation assay of SGC-7901 and MGC-803 cells after treatment with miR-133b mimics or miR-133b nc. For all qPCR results, the data are presented as the mean ± SEM, and the error bars represent the standard deviation obtained from three independent experiments. *p < 0.05; **p < 0.01.
Recently, Xue et al. reported that microRNA-133b (miR-133b) plays a suppressor role in several human cancers, as well as glioma [8], colorectal cancer [11]. MicroRNAs (miRNAs) are small noncoding RNAs that bind to mRNAs and regulate gene expression at the posttranscriptional level [5–7]. There are a lot of evidence revealing that miRNAs’ expression is maladjusted in many cancers, but more studies are needed to confirm how it affects tumorigenesis and metastasis. miRNAs can act as oncogenes or tumor suppressors to regulate the occurrence and development of tumors. For example, miR-218 [27], miR-129 [28], miR-148 [29], and miR-7a [30] were considered as tumor suppressor.
However, miR-21 [31], miR-221 [32], miR-214 [33], miR-34b [34], and miR-352 [35] were considered as oncogenes in GC [31–35]. In this study, we aimed to study the clinical diagnostic value of HuR and miR-133b in GC.

**Abbreviations**

GC: Gastric cancer
HuR: Human antigen receptor
VHL: Von Hippel Lindau tumor suppressor
cox-2: Cyclooxygenase 2
MMP-9: Matrix metallopeptidase-9
miRNA: MicroRNA.

**Data Availability**

You can request the data by contacting the author's email address: lifenglover@sina.com

**Additional Points**

Statistics. All experiments were repeated at least three times. Statistical analyses were evaluated by the two-tailed t-test and one-way ANOVA. Statistically significance was set at \( p < 0.05 \) using SPSS program (SPSS 15.0, USA).

**Conflicts of Interest**

The authors disclose no potential conflicts of interest.

**Authors’ Contributions**

Jing Cui, Nanjing Cao, and Guochao Wang contributed equally to this work.

**Acknowledgments**

Feng Li designed and performed the experiments, interpreted data, and wrote the manuscript; Jing Cui and Nanjing Cao performed bioinformatics analysis; Guochao Wang and Fuhua Wang provided the experimental material of gastric cancer patients and healthy donors; Bin Yang and Jian Wang helped collect the samples and perform partial experiments. Yunqing Chen and Yongqiang Lv designed the study, directed the experiments, and wrote the manuscript. All authors read and approved the manuscript. This work was supported by grants from the Key Research and Development (R&D) Projects of Shanxi Province (201803D31166 to Feng Li), the Science and Technology Department Basic Research Project of Shanxi (201801D121303 to Feng Li), the PhD Foundation of Shanxi Cancer Hospital-Institute (2017A07 to Feng Li), the scientific research of Health Commission of Shanxi Province (2019062 to Yunqing Chen), and the scientific research and innovation team construction project of Shanxi Cancer Hospital (2020 to Feng Li).

**References**

[1] Z. Zhu, H. Huqin, and X. Wang, "Advances in the application of tumor autoantibodies in early diagnosis and screening of gastric cancer," Guangdong Medical Journal, vol. 37, no. 15, pp. 2358–2360, 2016.
[2] O. Yangxi and T. Hao, “Lymph node micrometastasis in gastric cancer: research advances,” Chinese Journal of General Surgery, vol. 24, no. 4, pp. 589–592, 2015.
[3] H. H. Kim, K. Abdelmohsen, A. Lal et al., "Nuclear HuR accumulation through phosphorylation by Cdk1," Genes & Development, vol. 22, no. 13, pp. 1804–1815, 2008.
[4] W. J. Ma, S. Cheng, C. Campbell, A. Wright, and H. Furneaux, "Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein," The Journal of Biological Chemistry, vol. 271, no. 14, pp. 8144–8151, 1996.
[5] J. Mrena, J. P. Wiksten, A. Kokkolä, A. Ristimäki, and C. Haglund, “COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer,” Tumour Biology, vol. 31, no. 1, pp. 1–7, 2010.
[6] Y.-H. Cui, Q.-Y. Feng, and Q. Liu, “Posttranscriptional regulation of MMP-9 by HuR contributes to IL-1ß-induced pterygium fibroblast migration and invasion,” Journal of Cellular Physiology, vol. 11, no. 6, 2019.
[7] Y. Qin, Y. Zhang, Q. Tang, L. Jin, and Y. Chen, "SQLE induces epithelial-to-mesenchymal transition by regulating of miR-133b in esophageal squamous cell carcinoma," Acta biochimica et biophysica Sinica, vol. 49, no. 2, pp. 138–148, 2017.
[8] K. Xue, J. Yang, J. Hu, J. Liu, and X. Li, “MicroRNA-133b expression associates with clinicopathological features and prognosis in glioma,” Artificial Cells, Nanomedicine, and Biotechnology, vol. 46, no. 4, pp. 815–818, 2018.
[9] I. Grammatikakis, K. Abdelmohsen, and M. Gorospe, "Post-translational control of HuR function," RNA, vol. 8, no. 1, 2017.
[10] J. Y. Pan, C. C. Sun, Z. Y. Bi et al., “miR-206/133b cluster: a weapon against lung cancer?,” Molecular Therapy-Nucleic Acids, vol. 8, no. 8, pp. 442–449, 2017.
[11] K. M. Xiang and X. R. Li, “miR-133b acts as a tumor suppressor and negatively regulates TBPL1 in colorectal cancer cells,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 8, pp. 3767–3772, 2014.
[12] M. Masè, M. Grasso, L. U. Avogaro et al., "Upregulation of miR-133b and miR-328 in patients with atrial dilatation: implications for stretch-induced atrial fibrillation," Frontiers in Physiology, vol. 10, no. 10, p. 1133, 2019.
[13] L. Lv, Q. Li, S. Chen et al., "miR-133b suppresses colorectal cancer cell stemness and chemoresistance by targeting methyltransferase DOT1L," Experimental Cell Research, vol. 385, no. 1, article 111597, 2019.
[14] J. Li, N. Zhang, R. Zhang et al., “CDCSL promotes hTERT expression and colorectal tumor growth,” Cellular Physiology and Biochemistry, vol. 41, no. 6, pp. 2475–2488, 2017.
[15] H. Qiu, X. Zhang, W. Ni et al., "Expression and clinical role of Cdc5L as a novel cell cycle protein in hepatocellular carcinoma," Digestive Diseases and Sciences, vol. 61, no. 3, pp. 795–805, 2016.
[16] A. Zuluetta, A. Caretti, P. Signorelli, and R. Ghidoni, "Resveratrol: a potential challenger against gastric cancer," World Journal of Gastroenterology: WJG, vol. 21, no. 37, pp. 10636–10643, 2015.
[17] Q. Zhao, Y. Li, J. Wang et al., “Concurrent neoadjuvant chemoradiotherapy for Siewert II and III adenocarcinoma at gastroesophageal junction," The American Journal of the Medical Sciences, vol. 349, no. 6, pp. 472–476, 2015.
A. Tozzi, C. Iftode, L. Cozzi et al., “Neoadjuvant chemoradiotherapy with volumetric-modulated arc therapy for medium-distal oesophageal and gastro-oesophageal junction carcinoma,” *Anticancer Research*, vol. 35, no. 7, pp. 4109–4116, 2015.

L. Lowenfeld, J. Datta, R. S. Lewis et al., “Multimodality treatment of T4 gastric cancer in the United States: utilization trends and impact on survival,” *Annals of Surgical Oncology*, vol. 22, Supplement 3, pp. 863–872, 2015.

F. Li, P. Yi, J. Pi et al., “QK15-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis,” *Oncotarget*, vol. 7, no. 22, pp. 32821–32834, 2016.

W. Eberhardt, U. Nasrullah, and K. Haeussler, “Inhibition of caspase-2 translation by the mRNA binding protein HuR: a novel path of therapy resistance in colon carcinoma cells?” *Cell*, vol. 8, no. 8, pp. 797–818, 2019.

D. Ostareck and A. Ostareck-Lederer, “RNA-binding proteins in the control of LPS-induced macrophase response,” *Frontiers in Genetics*, vol. 10, no. 31, 2019.

C. Giaginis, P. Alexandrou, N. Tsoukalas et al., “Hu-antigen receptor (HuR) and cyclooxygenase-2 (COX-2) expression in human non-small cell lung carcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival,” *Tumour*, vol. 36, no. 1, pp. 315–327, 2015.

T. Xiyu, B. Lingu, J. Kaiyan et al., “CUGBP1 and HuR regulate E-cadherin translation by altering recruitment of E-cadherin 2 mRNA to processing bodies and modulate epithelial barrier function,” *American Journal of Physiology. Cell Physiology*, vol. 310, no. 1, pp. 54–65, 2016.

M. J. Kang, B. K. Ryu, M. G. Lee et al., “NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis,” *Gastroenterology*, vol. 135, no. 6, pp. 2030–2042.e3, 2008.

J. Wei, Z. Wang, Z. Wang et al., “MicroRNA-31 function as a suppressor was regulated by epigenetic mechanisms in gastric cancer,” *BioMed Research International*, vol. 2017, Article ID 5348490, 11 pages, 2017.

M. Deng, C. Zeng, X. Lu et al., “miR-218 suppresses gastric cancer cell cycle progression through the CDK6/cyclin D1/E2F1 axis in a feedback loop,” *Cancer Letters*, vol. 403, no. 403, pp. 175–185, 2017.

C. Lu, Z. Shan, C. Li, and L. Yang, “MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp,” *Biomedicine & Pharmacotherapy*, vol. 86, pp. 450–456, 2017.

Y. Song, J. Sun, Y. Xu et al., “Microarray analysis of long non-coding RNAs related to microRNA-148b in gastric cancer,” *Neoplasma*, vol. 64, no. 2, pp. 199–208, 2017.

B. M. Kim, J. Woo, C. Kanellopoulou, and R. A. Shivdasani, “Regulation of mouse stomach development and Barx1 expression by specific microRNAs,” *Development*, vol. 138, no. 6, pp. 1081–1086, 2011.

P. Zheng, L. Chen, X. Yuan et al., “Exosomal transfer of tumor-associated macrophase-derived miR-21 confers cisplatin resistance in gastric cancer cells,” *Journal of Experimental & Clinical Cancer Research*, vol. 36, no. 1, p. 53, 2017.

T. Ning, H. Zhang, X. Wang et al., “miR-221 and miR-222 synergistically regulate hepatocyte growth factor activator inhibitor type 1 to promote cell proliferation and migration in gastric cancer,” *Tumour Biology*, vol. 39, no. 6, p. 1010428317701636, 2017.